X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This collaboration strengthens Akron’s portfolio of off-the-shelf gene editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene modified cell therapies including VOR33.
Lead Product(s): Engineered Human Stem Cell Therapy,Ozogamicin
Therapeutic Area: Oncology Product Name: VOR33
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vor Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 22, 2022
Details:
Partnership Aims to Enhance Safety of Human Serum from Viruses. Under the agreement, Akron Biotech will produce Human AB Serum converted from Octaplas®, which is Octapharma’s pooled, solvent/detergent treated human plasma product.
Lead Product(s): Virally inactivated human AB serum
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Octapharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 20, 2021
Details:
Akron will support the future clinical and commercial development of SNG001 through the provision of its IFN-beta in Synairgen’s formulation.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Product Name: SNG001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Synairgen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
